肠道菌群失调与皮肤科常见结缔组织病相关性概述

doi:10.35541/cjd.20190082

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (4): 308-311.doi: 10.35541/cjd.20190082

肠道菌群失调与皮肤科常见结缔组织病相关性概述

于尧¹ 韩毓梅² 周金哲³ 李兰英¹

¹同济大学附属上海市第四人民医院皮肤科 200080；²复旦大学附属中山医院皮肤科，上海 200030；³上海市第十人民医院普外科 200040

收稿日期:2018-12-03 修回日期:2019-06-17 发布日期:2020-04-01
通讯作者: 李兰英 E-mail:Sy-lly@hotmail.com

An overview of correlations between intestinal flora imbalance and common connective tissue diseases in dermatology

Yu Yao¹, Han Yumei², Zhou Jinzhe³, Li Lanying¹

¹Department of Dermatology, Shanghai Fourth People′s Hospital, Shanghai 200080, China; ²Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai 200030, China; ³Department of General Surgery, Shanghai Tenth People′s Hospital, Shanghai 200040, China

Received:2018-12-03 Revised:2019-06-17 Published:2020-04-01
Contact: Li Lanying E-mail:Sy-lly@hotmail.com

摘要/Abstract

摘要： 【摘要】越来越多的研究发现，肠道菌群与结缔组织病具有相关性。本文概述肠道菌群的特点及其在结缔组织病中的作用机制，重点阐述肠道菌群失调在红斑狼疮、系统性硬化病、干燥综合征中的相关性、可能作用机制及相关假说。通过益生菌调节肠道菌群失调可作为这些常见结缔组织病的治疗手段之一。

关键词: 红斑狼疮, 系统性；硬皮病, 系统性；干燥综合征；微生物群落；肠道菌群

Abstract: 【Abstract】 More and more studies have found that intestinal flora is associated with connective tissue diseases. This review summarizes characteristics of intestinal flora and its mechanism of action in connective tissue diseases, and mainly elaborates correlations between intestinal flora imbalance and 3 common connective tissue diseases （lupus erythematosus, systemic scleroderma and Sjogren′s syndrome）, its possible mechanism of action and related hypothesis. Probiotics can regulate the intestinal flora imbalance, and serve as one of treatments for these common connective tissue diseases.

Key words: Lupus erythematosus, systemic, Scleroderma, systemic, Sjogren′s syndrome, Microbial consortia, Intestinal microbiota

于尧韩毓梅周金哲李兰英. 肠道菌群失调与皮肤科常见结缔组织病相关性概述[J]. 中华皮肤科杂志, 2020,53(4):308-311. doi:10.35541/cjd.20190082

Yu Yao, Han Yumei, Zhou Jinzhe, Li Lanying. An overview of correlations between intestinal flora imbalance and common connective tissue diseases in dermatology[J]. Chinese Journal of Dermatology, 2020, 53(4): 308-311.doi:10.35541/cjd.20190082

参考文献 33

［1］	Belizário JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches［J］. Front Microbiol, 2015,6:1050. doi: 10.3389/fmicb.2015. 01050.
［2］	Yurkovetskiy LA, Pickard JM, Chervonsky AV. Microbiota and autoimmunity: exploring new avenues［J］. Cell Host Microbe, 2015,17（5）:548⁃552. doi: 10.1016/j.chom.2015.04.010.
［3］	Human Microbiome Project Consortium. A framework for human microbiome research［J］. Nature, 2012,486（7402）:215⁃221. doi: 10.1038/nature11209.
［4］	Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome［J］. Nature, 2012,486（7402）:207⁃214. doi: 10.1038/nature11234.
［5］	Zoetendal EG, Rajilic⁃Stojanovic M, de Vos WM. High⁃throughput diversity and functionality analysis of the gastrointestinal tract microbiota［J］. Gut, 2008,57（11）:1605⁃1615. doi: 10.1136/gut.2007.133603.
［6］	Segata N, Haake SK, Mannon P, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples［J］. Genome Biol, 2012,13（6）:R42. doi: 10.1186/gb⁃2012⁃13⁃6⁃r42.
［7］	Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome［J］. Nature, 2011,473（7346）:174⁃180. doi: 10.1038/nature09944.
［8］	Tsigalou C, Stavropoulou E, Bezirtzoglou E. Current insights in microbiome shifts in Sjogren′s syndrome and possible therapeutic interventions［J］. Front Immunol, 2018,9:1106. doi: 10.3389/fimmu.2018.01106.
［9］	Dwivedi M, Kemp EH, Laddha NC, et al. Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics［J］. Autoimmun Rev, 2015,14（1）:49⁃56. doi: 10.1016/j.autrev.2014. 10.002.
［10］	Zhang H, Liao X, Sparks JB, et al. Dynamics of gut microbiota in autoimmune lupus［J］. Appl Environ Microbiol, 2014,80（24）:7551⁃7560. doi: 10.1128/AEM.02676⁃14.
［11］	Mu Q, Zhang H, Liao X, et al. Control of lupus nephritis by changes of gut microbiota［J］. Microbiome, 2017,5（1）:73. doi: 10.1186/s40168⁃017⁃0300⁃8.
［12］	Hevia A, Milani C, López P, et al. Intestinal dysbiosis associated with systemic lupus erythematosus［J］. MBio, 2014,5（5）:e01548⁃14. doi: 10.1128/mBio.01548⁃14.
［13］	López P, Sánchez B, Margolles A, et al. Intestinal dysbiosis in systemic lupus erythematosus: cause or consequence?［J］. Curr Opin Rheumatol, 2016,28（5）:515⁃522. doi: 10.1097/BOR.0000 000000000309.
［14］	López P, de Paz B, Rodríguez⁃Carrio J, et al. Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients［J］. Sci Rep, 2016,6:24072. doi: 10.1038/srep24072.
［15］	Yacoub R, Jacob A, Wlaschin J, et al. Lupus: the microbiome angle［J］. Immunobiology, 2018,223（6⁃7）:460⁃465. doi: 10.1016/ j.imbio.2017.11.004.
［16］	Neuman H, Koren O. The gut microbiota: a possible factor influencing systemic lupus erythematosus［J］. Curr Opin Rheumatol, 2017,29（4）:374⁃377. doi: 10.1097/BOR.00000000 00000395.
［17］	Mu Q, Zhang H, Luo XM. SLE: another autoimmune disorder influenced by microbes and diet?［J］. Front Immunol, 2015,6:608. doi: 10.3389/fimmu.2015.00608.
［18］	Versini M, Jeandel PY, Bashi T, et al. Unraveling the hygiene hypothesis of helminthes and autoimmunity: origins, patho⁃physiology, and clinical applications［J］. BMC Med, 2015,13:81. doi: 10.1186/s12916⁃015⁃0306⁃7.
［19］	Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system［J］. Nature, 2011,474（7351）:327⁃336. doi: 10.1038/nature10213.
［20］	Geuking MB, Cahenzli J, Lawson MA, et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses［J］. Immunity, 2011,34（5）:794⁃806. doi: 10.1016/j.immuni.2011. 03.021.
［21］	Mehta H, Goulet PO, Mashiko S, et al. Early⁃life antibiotic exposure causes intestinal dysbiosis and exacerbates skin and lung pathology in experimental systemic sclerosis［J］. J Invest Dermatol, 2017,137（11）:2316⁃2325. doi: 10.1016/j.jid.2017.06. 019.
［22］	Andréasson K, Alrawi Z, Persson A, et al. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease［J］. Arthritis Res Ther, 2016,18（1）:278. doi: 10.1186/s13075⁃016⁃1182⁃z.
［23］	Volkmann ER, Hoffmann⁃Vold AM, Chang YL, et al. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts［J］. BMJ Open Gastroenterol, 2017,4（1）:e000134. doi: 10.1136/bmjgast⁃2017⁃000134.
［24］	Volkmann ER. Intestinal microbiome in scleroderma: recent progress［J］. Curr Opin Rheumatol, 2017,29（6）:553⁃560. doi: 10.1097/BOR.0000000000000429.
［25］	Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn′s disease: a multicentre inception cohort study［J］. Lancet, 2017,389（10080）:1710⁃1718. doi: 10.1016/S0140⁃6736（17）30317⁃3.
［26］	Bellocchi C, Volkmann ER. Update on the gastrointestinal microbiome in systemic sclerosis［J］. Curr Rheumatol Rep, 2018,20（8）:49. doi: 10.1007/s11926⁃018⁃0758⁃9.
［27］	Park JS, Choi JW, Jhun J, et al. Lactobacillus acidophilus improves intestinal inflammation in an acute colitis mouse model by regulation of Th17 and Treg cell balance and fibrosis development［J］. J Med Food, 2018,21（3）:215⁃224. doi: 10.1089/ jmf.2017.3990.
［28］	Frech TM, Khanna D, Maranian P, et al. Probiotics for the treatment of systemic sclerosis⁃associated gastrointestinal bloating/ distention［J］. Clin Exp Rheumatol, 2011,29（2 Suppl 65）:S22⁃25.
［29］	de Paiva CS, Jones DB, Stern ME, et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome［J］. Sci Rep, 2016,6:23561. doi: 10.1038/srep23561.
［30］	Mandl T, Marsal J, Olsson P, et al. Severe intestinal dysbiosis is prevalent in primary Sjögren′s syndrome and is associated with systemic disease activity［J］. Arthritis Res Ther, 2017,19（1）:237. doi: 10.1186/s13075⁃017⁃1446⁃2.
［31］	Stavropoulou E, Bezirtzoglou E. Human microbiota in aging and infection: a review［J］. Crit Rev Food Sci Nutr, 2019,59（4）:537⁃545. doi: 10.1080/10408398.2017.1379469.
［32］	West CE, Renz H, Jenmalm MC, et al. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies［J］. J Allergy Clin Immunol, 2015,135（1）:3⁃14. doi: 10.1016/j.jaci.2014. 11.012.
［33］	Wopereis H, Sim K, Shaw A, et al. Intestinal microbiota in infants at high risk for allergy: effects of prebiotics and role in eczema development［J］. J Allergy Clin Immunol, 2018,141（4）:1334⁃1342.e5. doi: 10.1016/j.jaci.2017.05.054.

[1]	罗帅寒天龙海陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023, 56(3): 266-269.
[2]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220271-e20220271.
[3]	王琪坚哲. 间充质干细胞三维培养技术及其在皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230083-e20230083.
[4]	胡颖焦晴晴. 记忆性T细胞在慢性自身免疫性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230193-e20230193.
[5]	万立陈金波姜倩陈红英胡彬陈柳青. 反射式共聚焦显微镜在界面皮炎中的应用研究进展[J]. 中华皮肤科杂志, 2023, 56(10): 982-985.
[6]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[7]	罗帅寒天龙海陆前进, . 2021年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2022, 55(4): 369-372.
[8]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[9]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.
[10]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[11]	罗帅寒天龙海张桂英陆前进. 2019年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(2): 183-186.
[12]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2021, 54(2): 116-121.
[13]	罗帅寒天龙海陆前进. 2018年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2020, 53(8): 665-667.
[14]	仲志婷苗青青蒋柱燕张梦洁唐隽. circ-PTPN22在系统性红斑狼疮患者外周血单个核细胞中的翻译及意义[J]. 中华皮肤科杂志, 2020, 53(7): 525-532.
[15]	李泓馨赵勇胡瑾刘晓雁. 13例新生儿红斑狼疮的临床特征、皮损后遗表现[J]. 中华皮肤科杂志, 2020, 53(10): 787-790.

肠道菌群失调与皮肤科常见结缔组织病相关性概述

An overview of correlations between intestinal flora imbalance and common connective tissue diseases in dermatology

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

Metrics

本文评价

推荐阅读 10